PubMed Health⌕ Search

PubMed · 14967655

Genotypic differences in water use efficiency and (13)C discrimination in Eucalyptus globulus.

Abstract

Cuttings of three Eucalyptus globulus Labill. clones (called SM, VC, DG henceforward) were grown for 56 days in 10-l pots in a greenhouse. Every other day, eight pots of each clone were watered to field capacity (HW treatment), whereas the other eight pots of each clone received only 25% of the water needed to maintain the soil at field capacity (LW treatment). Transpirational water loss, biomass production, leaf gas exchange and water potential (at predawn and midday) were determined at different times during the experiment. Leaf tissue formed by the LW plants after the onset of the treatment was analyzed for (13)C/(12)C ratio against the PeeDee Belemnite standard (delta(13)C). The three clones differed significantly in growth capacity (SM > DG > VC) and in their response to water stress. Even though leaf water potentials were not significantly modified by withholding water, total biomass and plant leaf area were affected significantly by soil water deficits by the end of the experiment. The fastest growing clone (SM) was the most affected by water deficit. Long-term water use efficiency (i.e., biomass per unit of water transpired, WUE) was significantly increased by water deficit and was positively correlated with delta(13)C. Long-term WUE was well correlated with the quotient of the daily integrals of carbon assimilation rate and stomatal conductance. The value of delta(13)C was negatively correlated with the variables normally positively related with growth, such as specific leaf area (SLA) and the biomass/intercepted light quotient (epsilon), and it was positively related to the amount of carbon per unit leaf area, which is usually negatively correlated with relative growth rate.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J. Osório, J. S. Pereira. Genotypic differences in water use efficiency and (13)C discrimination in Eucalyptus globulus.. https://doi.org/10.1093/treephys%2F14.7-8-9.871

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗